mardez678

Total Rating:
0 / 0

1 Comment

    • Thu Feb 7th 14:46 PM | Rating: 0 0
      Commented on:
      Isis-Genzyme: Deal of the Year?
      Company insiders are allowed to buy stock only within a very narrowly defined time frame per SEC rules because they are privy to insider information.

      When you invest in Biotech you must have a ten year, or more, time frame. This is about the time it takes for a drug to get to market - if at all.

      ISIS is the first biotech drug I have ever invested in and I did so because of the science. It is innovative and looks at an aspect of our DNA/RNA makeup that reveals a potential to stop disease by stopping or turning off certain protein production functions specific to a certain disease and thereby preventing or stopping the disease.

      Who else beleives that they can do this?

      These companies: EI Lilly, Alnylam, Ortho-Mcneil, Bristol Myers Squibb, J & J, Pfizer, Achaogen, Merck & Co., Antisense Therapeutics, Atlantic, Healthcare(UK), iCO, ImQuest Pharmaceuticals, OncoGenex, Sarissa, Archemix, Ercole Biotec, Rosetta Genomics, Santaris Pharma, Idera Pharma, Integrated DNA Tech., Drug Royalty USA, Inc., Eyetech Pharma and finally there is IBIS, which manufactures the T5000, which can identify bacteria and virus in human clinical samples and give an antidote or a cure in a few hours. This last was essentially purchased by Abbott last month.

      Should you own ISIS - only if you have patience and the willingness to stick with a formidable bio-tech company that has cutting edge technology to cure and prevent disease from opthalmic to cancer.

      Disclosure: writer has common and call options on ISIS.
      View article »
Contribute an Article Become a Seeking Alpha Contributor